Last reviewed · How we verify
ribavirin pre-treatment
Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate metabolism and RNA-dependent RNA polymerase activity.
Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate metabolism and RNA-dependent RNA polymerase activity. Used for Chronic hepatitis C virus infection (pre-treatment prior to interferon-based therapy), Respiratory syncytial virus infection (off-label use).
At a glance
| Generic name | ribavirin pre-treatment |
|---|---|
| Also known as | ribavirin pre treatment, ribavirin priming, Recurrence of hepatitis c, hepatitis c, transplanted patients |
| Sponsor | University of Roma La Sapienza |
| Drug class | Nucleoside analog antiviral |
| Target | Viral RNA-dependent RNA polymerase; guanosine triphosphate metabolism |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ribavirin is a broad-spectrum antiviral agent that acts as a guanosine analog, depleting intracellular guanosine triphosphate pools and directly inhibiting viral RNA polymerases. When used as pre-treatment, it aims to establish antiviral activity prior to primary therapeutic intervention, particularly in chronic hepatitis C virus infection where it enhances sustained virological response rates when combined with interferon-based regimens.
Approved indications
- Chronic hepatitis C virus infection (pre-treatment prior to interferon-based therapy)
- Respiratory syncytial virus infection (off-label use)
Common side effects
- Hemolytic anemia
- Fatigue
- Headache
- Nausea
- Teratogenicity/reproductive toxicity
- Hyperuricemia
Key clinical trials
- Lassa Fever Clinical Course and Prognostic Factors in Nigeria
- Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021) (PHASE2)
- Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers (EARLY_PHASE1)
- DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) (PHASE4)
- A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (PHASE2, PHASE3)
- Telaprevir in Genotype 3 HCV (PHASE4)
- Bioequivalence Study of Ribavirin in Healthy Adult Subjects Under Fed Condition (PHASE1)
- Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ribavirin pre-treatment CI brief — competitive landscape report
- ribavirin pre-treatment updates RSS · CI watch RSS
- University of Roma La Sapienza portfolio CI